Related Experiment Videos
Dyslipoproteinemia and diabetes
1Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, USA.
Endocrinology and Metabolism Clinics of North America
|October 24, 1998
Summary
Diabetic dyslipidemia, characterized by abnormal lipoproteins, increases atherosclerosis risk. A step-care approach using diet, exercise, and specific lipid-lowering drugs like statins is recommended, avoiding nicotinic acid.
Area of Science:
- Endocrinology
- Cardiovascular Medicine
- Pharmacology
Background:
- Diabetic dyslipidemia involves lipoprotein abnormalities, significantly contributing to atherosclerosis risk in diabetic patients.
- Effective management is crucial for reducing cardiovascular complications associated with diabetes.
Purpose of the Study:
- To outline a step-care therapeutic approach for managing dyslipidemia in patients with diabetes.
- To guide the selection of appropriate lipid-lowering medications based on hypertriglyceridemia severity.
Main Methods:
- Review of current therapeutic strategies for diabetic dyslipidemia.
- Emphasis on a multi-faceted approach including lifestyle modifications and pharmacotherapy.
- Categorization of lipid-lowering drugs based on efficacy and safety in diabetic patients.
Main Results:
- A step-care therapy is recommended, integrating hygienic measures (diet, physical activity), hypoglycemic drugs, and lipid-lowering agents.
- Statins and bile-acid-binding resins are primary choices for diabetic dyslipidemia.
- Fibric acid derivatives are indicated for severe hypertriglyceridemia; nicotinic acid should be avoided due to worsening hyperglycemia.
Conclusions:
- Diabetic dyslipidemia requires a tailored, step-care management plan.
- Drug selection for lipid management must consider the degree of hypertriglyceridemia and potential impact on glycemic control.
- Further research is needed to establish the role of estrogen replacement therapy in postmenopausal diabetic women.